HONG KONG SAR - Media OutReach Newswire – 5 February 2025 - AIM Vaccine Co., Ltd. (06660), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory ...

The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly ...

A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

A research team has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

A research team led by Professor Won Jong Kim from the Department of Chemistry at POSTECH, in collaboration with the Korea ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed ...

A freshman Idaho lawmaker wants to ban most COVID-19 shots for the next decade, with a bill rooted in misconceptions about vaccines that thrived during the pandemic. The bill from Sen. Brandon Shippy, ...

Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

Moderna (NASDAQ:MRNA – Free Report) had its price objective decreased by Evercore ISI from $60.00 to $50.00 in a research ...

“mRNA technology will complement existing vaccine technology ... but it’s possible for H5N1 to swap genetic material with a human seasonal flu virus and spawn a new form of influenza with pandemic ...